Aurinia Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $311.5M+32.5% YoYTTM through 30 Jun 2026
Net Income $314.1M+5,361.0% YoYTTM through 30 Jun 2026
Free Cash Flow $135.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 88.5% |
| EBITDA Margin | 54.6% |
| Operating Margin | 37.1% |
| Net Margin | 100.8% |
Returns
49.4%ROE
38.2%ROA
72.2%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.25x
Net Debt-$398Mnet cash position
Cash & Equivalents$179.7M
Quality Metrics
Altman Z-Score8.17
Piotroski F-Score5 / 9
FCF Margin43.5%
Rule of 4049.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $283.1M
Diluted EPS$2.29TTMFY2025: $2.07
Dividend
No dividend
Capital Allocation
R&D Spend$39.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| LUPKYNIS Product Sales | $271.3M | +25.5% | View detailsAdopted widely in the US market with continued expansion planned. |
| License, Collaboration and Royalty Revenue | $11.7M | -38.1% | View detailsPrior period (2024) included a one-time $10.0 million milestone payment for regulatory approval in Japan. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.